Literature DB >> 19924022

PKC Delta (PKCdelta) promotes tumoral progression of human ductal pancreatic cancer.

Laura V Mauro1, Valeria C Grossoni, Alejandro J Urtreger, Chengfeng Yang, Lucas L Colombo, Ana Morandi, María G Pallotta, Marcelo G Kazanietz, Elisa D Bal de Kier Joffé, Lydia L Puricelli.   

Abstract

OBJECTIVE: Our objective was to study the role of protein kinase C delta (PKCdelta) in the progression of human pancreatic carcinoma.
METHODS: Protein kinase C delta expression in human ductal carcinoma (n = 22) was studied by immunohistochemistry. We analyzed the effect of PKCdelta overexpression on in vivo and in vitro properties of human ductal carcinoma cell line PANC1.
RESULTS: Human ductal carcinomas showed PKCdelta overexpression compared with normal counterparts. In addition, in vitro PKCdelta-PANC1 cells showed increased anchorage-independent growth and higher resistance to serum starvation and to treatment with cytotoxic drugs. Using pharmacological inhibitors, we determined that phosphatidylinositol-3-kinase and extracellular receptor kinase pathways were involved in the proliferation of PKCdelta-PANC1. Interestingly, PKCdelta-PANC1 cells showed a less in vitro invasive ability and an impairment in their ability to migrate and to secrete the proteolytic enzyme matrix metalloproteinase-2. In vivo experiments indicated that PKCdelta-PANC1 cells were more tumorigenic, as they developed tumors with a significantly lower latency and a higher growth rate with respect to the tumors generated with control cells. Besides, only PKCdelta-PANC1 cells developed lung metastasis.
CONCLUSION: Our results showed that the overexpression of PKCdelta in PANC1 cells induced a more malignant phenotype in vivo, probably through the modulation of cell proliferation and survival, involving phosphatidylinositol-3-kinase and extracellular receptor kinase signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19924022     DOI: 10.1097/MPA.0b013e3181bce796

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  32 in total

Review 1.  Protein kinase C as a tumor suppressor.

Authors:  Alexandra C Newton
Journal:  Semin Cancer Biol       Date:  2017-05-02       Impact factor: 15.707

2.  Protein kinase Cδ is a therapeutic target in malignant melanoma with NRAS mutation.

Authors:  Asami Takashima; Brandon English; Zhihong Chen; Juxiang Cao; Rutao Cui; Robert M Williams; Douglas V Faller
Journal:  ACS Chem Biol       Date:  2014-02-18       Impact factor: 5.100

Review 3.  Protein kinase C: perfectly balanced.

Authors:  Alexandra C Newton
Journal:  Crit Rev Biochem Mol Biol       Date:  2018-04       Impact factor: 8.250

Review 4.  Protein kinase C and cancer: what we know and what we do not.

Authors:  R Garg; L G Benedetti; M B Abera; H Wang; M Abba; M G Kazanietz
Journal:  Oncogene       Date:  2013-12-16       Impact factor: 9.867

5.  PKCδ maintains phenotypes of tumor initiating cells through cytokine-mediated autocrine loop with positive feedback.

Authors:  R-K Kim; Y Suh; E Hwang; K-C Yoo; K-S Choi; S An; S-G Hwang; I-G Kim; M-J Kim; H-J Lee; S-J Lee
Journal:  Oncogene       Date:  2015-03-09       Impact factor: 9.867

Review 6.  Protein kinase C isoforms in the normal pancreas and in pancreatic disease.

Authors:  Alicia K Fleming; Peter Storz
Journal:  Cell Signal       Date:  2017-08-18       Impact factor: 4.315

7.  NF-κB and cancer: a paradigm of Yin-Yang.

Authors:  Gutian Xiao; Jing Fu
Journal:  Am J Cancer Res       Date:  2010-12-06       Impact factor: 6.166

Review 8.  Multifunctional roles of PKCδ: Opportunities for targeted therapy in human disease.

Authors:  Mary E Reyland; David N M Jones
Journal:  Pharmacol Ther       Date:  2016-05-11       Impact factor: 12.310

9.  Protein kinase Cδ is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer.

Authors:  B L Allen-Petersen; C J Carter; A M Ohm; M E Reyland
Journal:  Oncogene       Date:  2013-03-11       Impact factor: 9.867

Review 10.  Reversing the Paradigm: Protein Kinase C as a Tumor Suppressor.

Authors:  Alexandra C Newton; John Brognard
Journal:  Trends Pharmacol Sci       Date:  2017-03-08       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.